N-acetyl cysteine + alpha lipoic acid + liposomal glutathione + GSK influenza vaccine

The combination of **N-acetyl cysteine (NAC)**, **alpha-lipoic acid (ALA)**, and **liposomal glutathione** associated with **GlaxoSmithKline (GSK)** influenza research refers to a nutritional and pharmacological strategy intended to enhance the immune response to influenza vaccines, particularly in elderly populations. NAC serves as a precursor to glutathione, while ALA is a potent metabolic antioxidant that helps regenerate endogenous antioxidants like glutathione and Vitamin E. Liposomal glutathione provides a direct, bioavailable source of the tripeptide. In the context of GSK's clinical development, such as the Phase 2 study of the adjuvanted influenza vaccine **GSK576389A**, these antioxidants are relevant due to their potential to mitigate immunosenescence and oxidative stress, which can impair vaccine efficacy in older adults. This combination aims to optimize the redox environment for T-cell and B-cell activation following vaccination with adjuvanted systems like AS03, which itself contains the antioxidant alpha-tocopherol.

Brand names

Fluarix

Other names

NAC + ALA + GSH + GSK influenza vaccineGlutathione Triad + Influenza Vaccine